FIA
TXMD icon

FNY Investment Advisers’s TherapeuticsMD TXMD Stock Holding History

FNY Investment Advisers’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-35
Closed -$4.93K – 1180
2019
Q2 		$4K Buy
+35
New +$6.27K ﹤0.01% 751
2018
Q4 		– Sell
-10
Closed -$2.44K – 1023
2018
Q3 		$3K Buy
+10
New +$3.06K ﹤0.01% 688

Other funds holding TXMD

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FNY Investment Advisers's TXMD Position: Q3 2019 in Review

FNY Investment Advisers sold out of TherapeuticsMD (TXMD) in Q3 2019, closing a stake of 35 shares — an estimated $4.93K sold.

FNY Investment Advisers first reported a position in TXMD in Q3 2018 and held it in 2 quarters. The position peaked at $4K in Q2 2019. 150 funds tracked by Wall St. Rank hold TXMD as of Q3 2019.

  • FNY Investment Advisers reported no remaining TherapeuticsMD position as of Q3 2019 after selling out during the quarter.
  • FNY Investment Advisers sold 35 TherapeuticsMD shares in Q3 2019, an estimated $4.93K.
  • FNY Investment Advisers first reported a position in TherapeuticsMD in Q3 2018 and held it in 2 quarters.
  • FNY Investment Advisers's TherapeuticsMD position peaked at $4K in Q2 2019.
  • 150 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2019.

Based on FNY Investment Advisers's 13F filing for Q3 2019, filed 25 Oct 2019.